Company intelligence / Profile preview

Everbeat

Ownership: Private
Development stage: Other

Overview

Everbeat has developed a novel wearable medical-grade cardiac monitor ("everbeat ring") capable of accurate dry-electrode ECG recordings and QT measurement. Early research demonstrates reliable detection of atrial fibrillation and potential for broader cardiovascular event identification. The company is preparing for FDA clearance and commercial launch in 2025[1][4].

Therapeutic areas: Cardiovascular
Modalities: DeviceDigital health platform
Industry: Physiological Monitoring

Partnerships

Product development partner based in Brooklyn

Beyond the preview

Go deeper on Everbeat.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Everbeat.

Explore the full profile